Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes

European Journal of Clinical Investigation

Volumn 34, Issue 1, 2004, Pages 29-36

  Robinson, A C J ^a,d   Jeffs, J A R ^a,d   Gray, R G ^a,d   Bannister, P A ^a,d   Mather, H ^b   Gallagher, J J ^a,d   Robinson, S ^a,d   Nattrass, M ^c   Venkatesan, S ^a,d   Halliday, D ^a,d   Johnston, D G ^a,d  

^a ST MARY S HOSPITAL   (United Kingdom)

^b EALING HOSPITAL   (United Kingdom)

^c SELLY OAK HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

NEFA; PPAR agonists; Triglyceride; Troglitazone; Type 2 diabetes; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B100; CARBON 13; FATTY ACID; GLUCOSE; GLYCEROL; HEMOGLOBIN A1C; INSULIN; ISOTOPE; LEUCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRIACYLGLYCEROL; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; GEOMETRY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN INFUSION; ISOTOPE ANALYSIS; KINETICS; LIPID ANALYSIS; LIPID METABOLISM; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; GLYCEROL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOLYSIS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 10744228248     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01274.x     Document Type: Article

References (42)

1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
2. Ferrannini E, Balkan B. Insulin: in search of a syndrome. Diabet Med 2002: 19724-9.
3. Pyrörälä K, Laakso M, Uusitupa M. Diabetes and artherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
4. Hollenbeck CB, Chen N, Chen YDI, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 1984;33:460-3.
5. Chen YDI, Reaven GM. Insulin resistance and atherosclerosis. Diabetes Rev 1997;5:331-42.
6. Tataranni PA, Baier LJ, Paolisso G, Howard BV, Ravussin E. Role of lipids in development of noninsulin-dependent diabetes mellitus: lessons learned from Pima Indians. Lipids 1996;31:267-70.
7. Christiansen MP, Linfoot PA, Neese RA, Hellerstein MK. Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. Diabetes 2000;49:1691-9.
8. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995;38:959-67.
9. UKPDS. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
10. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
11. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, Fanghanel-Salmon G, Gallegos-Martinez J, Gomez-Diaz RA et al. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism 2002;51:44-51.
12. Komers R, Vrana A. Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res 1998;47:215-25.
13. Anyaoku V, Johnston DG. Rapid, specific and sensitive enzyme-linked immunosorbent assay for intact human insulin. Diabetologia 1995;38:A157.
14. Havel RJ, Elder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
15. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993;13:1110-8.
16. Ford GC, Cheng KN, Halliday D. Analysis of (1-13C) leucine and (13C) KIC in plasma by capillary gas chromatography/mass spectrometry in protein turnover studies. Biomed Mass Spectrometry 1985;12:432-6.
17. Chrisoulidou A, Kousta E, Venkatesan S, Gray R, Bannister PA, Gallagher JJ et al. Effects of growth hormone treatment on very-low density lipoprotein apolipoprotein B100 turnover in adult hypopituitarism. Metabolism 2000;49:563-6.
18. Cobelli C, Toffolo G, Bier DM, Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol 1987;253:E551-64.
19. Gelding SV, Coldham N, Anyaoku V, Heslop K, Halliday D, Johnston DG. Differential metabolic actions of biosynthetic insulin analogues in normal man assessed by stable isotopic tracers. Diabet Med 1993;10:470-6.
20. Wiico J, Storman WR. Boroacetylation of carboxyhydrates. Correlation between structure and mass spectral behaviour in monoacetyl-hexosl cyclic boronic stars. J Am Chem Soc 1976;98:7631-9.
21. Magni F, Arnoldi L, Monti L, Piatti P, Pozza G, Galli Kienle M. Determination of plasma glycerol isotopic enrichment by gas chromatography-mass spectrometry: an alternative glycerol derivative. Anal Biochem 1993;211:327-8.
22. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1991;11:147-53.
23. Howard BV. Pathogenesis of diabetic dyslipidemia. Diabetes Rev 1995;3:423-32.
24. Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990;10:223-31.
25. Taskinen MR. Hyperlipidemia in diabetes. Ballieres Clin Endocrinol Metab 1990;4:743-75.
26. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997;46:433-9.
27. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
28. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-6.
29. Diamant M, Heine R. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-405.
30. Van Wijk JP, De Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in Type 2 diabetes. A summary analysis. Arterioscler Thromb Biol 2003;23:1744-9.
31. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR et al. Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52.
32. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S et al. A randomized, double-blind, placebo-controlled, clinical trial into the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95.
33. Kearney T, Navas de Gallegos C, Proudler A, Parker K, Anyaoku V, Bannister P et al. Effects of long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects. Metabolism 2003;52:50-9.
34. Demant T, Packard C, Patsch J. In Vivo Studies of VLDL Metabolism and LDL Heterogeneity. European Heart Journal 1998;19 (Suppl. H): H7-H10.
35. Martin G, Schoonjans K, Staels B, Auwerx J. PPAR gamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998;137:875-80.
36. Willson TM, Lambert MH, Kleiner SA. Peroxisome proliferator-activated receptor and metabolic disease. Annu Rev Biochem 2001;70:341-67.
37. Gurnell M, Savage DB, Chatterjee KK, O'Rahilly S. The Metabolic Syndrome: peroxisome proliferator activated receptor y and its therapeutic modulation. J Clin Endocrinol Metab 2003;88:2412-21.
38. Lee CH, Olson P, Evans RM. Mini-review: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7.
39. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-85.
40. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR. Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 2003;285:E354-62.
41. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-66.
42. Krentz AJ, Nattrass M. Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique. Diabet Med 1996;13:30-9.